Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INO-5401 +/- INO-9012 Vaccine in BRCA1/2 Mutation Carriers
NCT04367675Phase 1Active, not recruiting
- Sponsor
- University of Pennsylvania
- Start
- Apr 2021
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, open-label trial of INO-5401 in hereditary breast and ovarian cancer syndrome (HBOC) (2 arms), sponsored by University of Pennsylvania. Primary endpoint: Dose Limiting Toxicities at 2 years. Started Apr 2021; status: active, not recruiting.
02
Drugs
INO-5401
03
Conditions
hereditary breast and ovarian cancer syndrome (HBOC)
Beyond the preview
Go deeper on NCT04367675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04367675.